Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B GOTTLIEB

Showing results (321-330 of 523) with videos related to

Pageof 53
Sort By:
Journal of the American Academy of Dermatology|January 11, 2003
Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgarisAlice B Gottlieb, Salman Masud, Rallapalli Ramamurthi, et al.
Journal of the American Academy of Dermatology|April 17, 2018
Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)Alice B Gottlieb, Andrew Blauvelt, Diamant Thaçi, et al.
The Journal of Rheumatology|July 15, 2023
Report of the Skin Research Workgroups From the IDEOM Breakout at the GRAPPA 2022 Annual MeetingMelissa P Zundell, Michael J Woodbury, Kathryn Lee, et al.
Journal of the American Academy of Dermatology|September 22, 2020
Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)Mark G Lebwohl, Craig L Leonardi, Nehal N Mehta, et al.
Molecular and Cellular Endocrinology|January 1, 1991
The 56/58 kDa androgen-binding protein in male genital skin fibroblasts with a deleted androgen receptor geneM Trifiro, B Gottlieb, L Pinsky, et al.
The British Journal of Dermatology|August 19, 2014
Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)A Blauvelt, J C Prinz, A B Gottlieb, et al.
Journal of the American Academy of Dermatology|September 17, 2019
Achieving consensus on patient-reported outcome measures in clinical practice for inflammatory skin disordersLourdes Perez-Chada, Vanina L Taliercio, Alice B Gottlieb, et al.
Experimental Cell Research|December 1, 1990
TGF-alpha and TGF-beta expression during sodium-N-butyrate-induced differentiation of human keratinocytes: evidence for subpopulation-specific up-regulation of TGF-beta mRNA in suprabasal cellsL Staiano-Coico, L Khandke, J F Krane, et al.
Journal of Drugs in Dermatology : JDD|July 8, 2015
Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)Kim Papp, Alice B Gottlieb, Luigi Naldi, et al.
Journal of the American Academy of Dermatology|January 14, 2015
WITHDRAWN: Experience with ustekinumab in patients with psoriasis enrolled in a large, multicenter, prospective, disease-based registry (Psoriasis Longitudinal Assessment and Registry [PSOLAR])Kim Papp, Alice B Gottlieb, Luigi Naldi, et al.
Pageof 53

Showing results (321-330 of 523) with videos related to

Sort By:
Pageof 53
Journal of the American Academy of Dermatology|January 11, 2003
Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgarisAlice B Gottlieb, Salman Masud, Rallapalli Ramamurthi, et al.
Journal of the American Academy of Dermatology|April 17, 2018
Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)Alice B Gottlieb, Andrew Blauvelt, Diamant Thaçi, et al.
The Journal of Rheumatology|July 15, 2023
Report of the Skin Research Workgroups From the IDEOM Breakout at the GRAPPA 2022 Annual MeetingMelissa P Zundell, Michael J Woodbury, Kathryn Lee, et al.
Journal of the American Academy of Dermatology|September 22, 2020
Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)Mark G Lebwohl, Craig L Leonardi, Nehal N Mehta, et al.
Molecular and Cellular Endocrinology|January 1, 1991
The 56/58 kDa androgen-binding protein in male genital skin fibroblasts with a deleted androgen receptor geneM Trifiro, B Gottlieb, L Pinsky, et al.
The British Journal of Dermatology|August 19, 2014
Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)A Blauvelt, J C Prinz, A B Gottlieb, et al.
Journal of the American Academy of Dermatology|September 17, 2019
Achieving consensus on patient-reported outcome measures in clinical practice for inflammatory skin disordersLourdes Perez-Chada, Vanina L Taliercio, Alice B Gottlieb, et al.
Experimental Cell Research|December 1, 1990
TGF-alpha and TGF-beta expression during sodium-N-butyrate-induced differentiation of human keratinocytes: evidence for subpopulation-specific up-regulation of TGF-beta mRNA in suprabasal cellsL Staiano-Coico, L Khandke, J F Krane, et al.
Journal of Drugs in Dermatology : JDD|July 8, 2015
Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)Kim Papp, Alice B Gottlieb, Luigi Naldi, et al.
Journal of the American Academy of Dermatology|January 14, 2015
WITHDRAWN: Experience with ustekinumab in patients with psoriasis enrolled in a large, multicenter, prospective, disease-based registry (Psoriasis Longitudinal Assessment and Registry [PSOLAR])Kim Papp, Alice B Gottlieb, Luigi Naldi, et al.
Pageof 53